Stock TNDM TANDEM DIABETES CARE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Tandem Diabetes Care, Inc.

Equities

TNDM

US8753722037

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
35.24 USD -0.90% Intraday chart for Tandem Diabetes Care, Inc. +15.81% +19.13%
Apr. 26 North American Morning Briefing : Tech Still in -2- DJ
Apr. 25 Leerink Partners Upgrades Tandem Diabetes Care to Outperform Rating, Price Target is $45 MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
TANDEM DIABETES CARE, INC. Stock Tandem Diabetes Care, Inc.
+19.13% 2.28B
B
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 187B
C+
MEDTRONIC PLC Stock Medtronic plc
-3.20% 106B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.9B
A
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 49.45B
B-
CENCORA, INC. Stock Cencora, Inc.
+17.29% 48B
B-
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
B+
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.25B
A-
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.48B
B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
A-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. TNDM Stock
  4. Ratings Tandem Diabetes Care, Inc.